UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Efficacy and safety of tanezumab in the treatment of chronic low back pain

Pain (Amsterdam), 2011-10, Vol.152 (10), p.2248-2258

2011

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain

Pain (Amsterdam), 2013-07, Vol.154 (7), p.1009-1021

2013

Link zum Volltext

Verfügbarkeit prüfen

Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety

Pain (Amsterdam), 2020-09, Vol.161 (9), p.2068-2078

2020

Link zum Volltext

Verfügbarkeit prüfen

Exploring the Role of Tanezumab as a Novel Treatment for the Relief of Neuropathic Pain

Pain medicine (Malden, Mass.), 2015-06, Vol.16 (6), p.1163-1176

2015

Link zum Volltext

Verfügbarkeit prüfen

Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3

Journal of clinical lipidology, 2024-03, Vol.18 (2), p.e261-e268

2024

Link zum Volltext

Verfügbarkeit prüfen

A multi‐purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo‐controlled, single‐ascending dose study in adults

Clinical and translational science, 2023-05, Vol.16 (5), p.886-897

2023

Link zum Volltext

Verfügbarkeit prüfen

Subphenotypes of self-reported symptoms and outcomes in long COVID: a prospective cohort study with latent class analysis

BMJ open, 2024-03, Vol.14 (3), p.e077869-e077869

2024

Link zum Volltext

Verfügbarkeit prüfen

Fibromyalgia syndrome

Journal of rheumatology, 2005-11, Vol.32 (11), p.2270

2005

Link zum Volltext

Verfügbarkeit prüfen

Lack of a pharmacokinetic interaction between azithromycin and chloroquine

The American journal of tropical medicine and hygiene, 2006-03, Vol.74 (3), p.407

2006

Link zum Volltext

Verfügbarkeit prüfen

Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

Circulation (New York, N.Y.), 2022-05, Vol.145 (18), p.1377-1386

2022

Link zum Volltext

Verfügbarkeit prüfen

HEPATIC FAT CHANGES AFTER AN ANTISENSE OLIGONUCLEOTIDE THERAPY TARGETING ANGPTL3: A TRANSLATE-TIMI 70 ANALYSIS

Journal of the American College of Cardiology, 2023-03, Vol.81 (8), p.1823-1823

2023

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain

Pain (Amsterdam), 2014-09, Vol.155 (9), p.1793-1801

2014

Link zum Volltext

Verfügbarkeit prüfen

A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment

Pain (Amsterdam), 2015-09, Vol.156 (9), p.1660-1669

2015

Link zum Volltext

Verfügbarkeit prüfen

419. Viral SARS-CoV-2 rebound rates in linked commercial pharmacy-based SARS-CoV-2 RT-qPCR testing and healthcare claims

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users

Pain medicine (Malden, Mass.), 2017-06, Vol.18 (6), p.1077-1088

2017

Link zum Volltext

Verfügbarkeit prüfen

Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users

Journal of clinical pharmacology, 2015-12, Vol.55 (12), p.1351-1361

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial

Pain and therapy, 2022-12, Vol.11 (4), p.1267-1285

2022

Link zum Volltext

Verfügbarkeit prüfen

Effects of Ethanol on the Pharmacokinetics of Extended-Release Oxycodone with Sequestered Naltrexone (ALO-02)

Clinical drug investigation, 2015-04, Vol.35 (4), p.267-274

2015

Link zum Volltext

Verfügbarkeit prüfen

Response to letter by Ackermann

Pain (Amsterdam), 2012-05, Vol.153 (5), p.1129-1131

2012

Link zum Volltext

Verfügbarkeit prüfen

Effect of Food on the Bioavailability of Amlodipine Besylate/Atorvastatin Calcium Combination Tablet

Journal of clinical pharmacology, 2006-10, Vol.46 (10), p.1212-1216

2006

Link zum Volltext

Verfügbarkeit prüfen

Bioavailability of Amlodipine Besylate/Atorvastatin Calcium Combination Tablet

Journal of clinical pharmacology, 2006-09, Vol.46 (9), p.1030-1037

2006

Link zum Volltext

Verfügbarkeit prüfen

Single- and multiple-dose study to evaluate pharmacokinetics, safety and tolerability in healthy volunteers: A comparison of extended-release oxycodone with sequestered naltrexone 40 mg twice daily to oxycontin 40 mg twice daily and extended-release oxycodone with sequestered naltrexone 80 mg once daily

Clinical pharmacology in drug development, 2015-09, Vol.4 (5), p.361-369

2015

Link zum Volltext

Verfügbarkeit prüfen

Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone

Clinical pharmacology in drug development, 2015-09, Vol.4 (5), p.370-376

2015

Link zum Volltext

Verfügbarkeit prüfen

Single- and multiple-dose study to evaluate pharmacokinetics, safety and tolerability in healthy volunteers: A comparison of extended-release oxycodone with sequestered naltrexone 40mg twice daily to oxycontin 40mg twice daily and extended-release oxycodone with sequestered naltrexone 80mg once daily

Clinical pharmacology in drug development, 2015-09, Vol.4 (5), p.361

2015

Link zum Volltext

Verfügbarkeit prüfen

A Single-Dose Pharmacokinetic Study of Lasofoxifene in Healthy Volunteers and Subjects With Mild and Moderate Hepatic Impairment

Journal of clinical pharmacology, 2006-01, Vol.46 (1), p.29-36

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(29)
Buchkapitel
(1)

Sprache

Englisch
(30)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of tanezumab in the treatment of chronic low back pain

Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain

Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety

Exploring the Role of Tanezumab as a Novel Treatment for the Relief of Neuropathic Pain

Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3

A multi‐purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo‐controlled, single‐ascending dose study in adults

Subphenotypes of self-reported symptoms and outcomes in long COVID: a prospective cohort study with latent class analysis

Fibromyalgia syndrome

Lack of a pharmacokinetic interaction between azithromycin and chloroquine

Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

HEPATIC FAT CHANGES AFTER AN ANTISENSE OLIGONUCLEOTIDE THERAPY TARGETING ANGPTL3: A TRANSLATE-TIMI 70 ANALYSIS

Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain

A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment

419. Viral SARS-CoV-2 rebound rates in linked commercial pharmacy-based SARS-CoV-2 RT-qPCR testing and healthcare claims

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users

Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users

Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial

Effects of Ethanol on the Pharmacokinetics of Extended-Release Oxycodone with Sequestered Naltrexone (ALO-02)

Response to letter by Ackermann

Effect of Food on the Bioavailability of Amlodipine Besylate/Atorvastatin Calcium Combination Tablet

Bioavailability of Amlodipine Besylate/Atorvastatin Calcium Combination Tablet

Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone

A Single-Dose Pharmacokinetic Study of Lasofoxifene in Healthy Volunteers and Subjects With Mild and Moderate Hepatic Impairment

Suchergebnisse filtern